Detail akcie Graft Polymer Rg online

Business Summary: Solvonis Therapeutics PLC is a clinical-stage biotechnology company developing treatments for addiction and mental health disorders. The Company is advancing a differentiated pipeline of repurposed and novel compounds targeting high-burden neuropsychiatric conditions with significant unmet need. It is focused on Alcohol Use Disorder (AUD), which affects over 40 million people across the United States, United Kingdom, and EU4 markets, and Post-Traumatic Stress Disorder (PTSD), impacting more than 13 million adults in the United States and approximately 20 million across those same regions. AUD is characterized by compulsive, harmful drinking, and is associated with significant health risks, including chronic diseases, mental health conditions and accidents, injuries and violence. PTSD is a complex and debilitating mental health condition that develops in some people who have experienced traumatic events, for example violence, an accident, war or a natural disaster.
Financial Summary: BRIEF: For the six months ended 30 June 2025, Solvonis Therapeutics PLC revenues was not reported. Net loss before extraordinary items increased from L469K to L1.6M. Higher net loss reflects Gain on deconsolidation decrease from L139K (income) to L0K.